Literature DB >> 33708113

Cerebrospinal Fluid Inflammatory Cytokine Levels in Patients With Major Psychiatric Disorders: A Multiplex Immunoassay Study.

Shinsuke Hidese1, Kotaro Hattori1,2, Daimei Sasayama1, Takuya Tsumagari1,2, Tomoko Miyakawa2, Ryo Matsumura2, Yuuki Yokota1,2, Ikki Ishida1, Junko Matsuo1, Sumiko Yoshida2,3, Miho Ota1, Hiroshi Kunugi1,4.   

Abstract

Aim: Accumulating evidence suggests that neural inflammation plays an important role in psychiatric disorders. We aimed to identify inflammatory cytokines involved in the pathophysiology of such disorders by quantifying them in cerebrospinal fluid (CSF) samples from a large sample of patients with major psychiatric disorders and healthy controls.
Methods: The subjects included 94 patients with schizophrenia, 68 with bipolar disorder, 104 with major depressive disorder, and 118 healthy controls, matched for age, sex, and ethnicity (Japanese). Lumbar puncture was performed to collect these CSF samples. A multiplex immunoassay was then performed to measure CSF cytokine levels using magnetic on-bead antibody conjugation for 19 inflammatory cytokines.
Results: CSF interferon-β level was significantly higher in total psychiatric patients than in healthy controls (corrected p = 0.000029). In diagnostic group comparisons, CSF interferon-β level was significantly higher in patients with schizophrenia, or bipolar disorder (corrected p = 0.000047 or 0.0034) than in healthy controls.
Conclusion: We present novel evidence that CSF IFN-β level showed prominent statistical differences between psychiatric groups and healthy controls. This suggests IFN-β as the most important player among the 19 cytokines tested here in the inflammation-related pathophysiology of major psychiatric disorders.
Copyright © 2021 Hidese, Hattori, Sasayama, Tsumagari, Miyakawa, Matsumurra, Yokota, Ishida, Matsuo, Yoshida, Ota and Kunugi.

Entities:  

Keywords:  bipolar disorder; cerebrospinal fluid; cytokine; major depressive disorder; multiplex; schizophrenia

Year:  2021        PMID: 33708113      PMCID: PMC7941212          DOI: 10.3389/fphar.2020.594394

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  5 in total

1.  Catalytic Antibodies in Bipolar Disorder: Serum IgGs Hydrolyze Myelin Basic Protein.

Authors:  Daria A Kamaeva; Liudmila P Smirnova; Svetlana N Vasilieva; Daria V Kazantseva; Alisa R Vasilieva; Svetlana A Ivanova
Journal:  Int J Mol Sci       Date:  2022-07-02       Impact factor: 6.208

2.  Neuroimmunological investigations of cerebrospinal fluid in patients with recent onset depression - a study protocol.

Authors:  Nina Vindegaard Sørensen; Sonja Orlovska-Waast; Rose Jeppesen; Rune Haubo Christensen; Michael Eriksen Benros
Journal:  BMC Psychiatry       Date:  2022-01-12       Impact factor: 3.630

3.  Gut permeability and its clinical relevance in schizophrenia.

Authors:  Ikki Ishida; Jun Ogura; Emiko Aizawa; Miho Ota; Shinsuke Hidese; Yukihito Yomogida; Junko Matsuo; Sumiko Yoshida; Hiroshi Kunugi
Journal:  Neuropsychopharmacol Rep       Date:  2022-01-25

4.  Association of body mass index and its classifications with gray matter volume in individuals with a wide range of body mass index group: A whole-brain magnetic resonance imaging study.

Authors:  Shinsuke Hidese; Miho Ota; Junko Matsuo; Ikki Ishida; Yuuki Yokota; Kotaro Hattori; Yukihito Yomogida; Hiroshi Kunugi
Journal:  Front Hum Neurosci       Date:  2022-09-08       Impact factor: 3.473

5.  Cerebrospinal fluid cytokines in geriatric patients with depressive disorders: A retrospective case-control study.

Authors:  Morten Brix Schou; Jeanette Brun Larsen; Astrid Kamilla Stunes; Sverre Georg Sæther
Journal:  Front Psychiatry       Date:  2022-09-12       Impact factor: 5.435

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.